Forte Biosciences (FBRX) Stock Price, Quote, News & History | Benzinga

Forte Biosciences Inc (FBRX) Stock Price, Quote, News & History

FBRXNASDAQ

Trade with Public

Trade with Public

$76.78

At close: Aug 13, 5:00 PM EST

$76.78

N/A

After Hours: 4:00 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

-

Volume / Avg.

0 / 1.07M

Day Range

- - -

52 Wk Range

9.91 - 77.20

Market Cap

$1.57B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

84

Short Interest

9.36%

Days to Cover

1

Recent Forte Biosciences Inc News

Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June

US stocks mixed in midday trading, Nasdaq falls 0.48%, Dow up 0.19%, S&P 500 down 0.23%. Consumer staples up 2%, tech down 1.9%. Durable goods orders rise 0.3%.

Avi Kapoor

Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover

Argenx is acquiring Forte Biosciences in a $2.2 billion all-cash deal. The $77 per share buyout expands its autoimmune drug portfolio.

Vandana Singh

Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday

Dow Jones up 400 points on Monday. Baker Hughes Co (BKR) shares rise after positive earnings and technology order. Other big gainers include NIPG, FBRX, TRAX, GENI, BMNR, OMER, ASAN, EIKN, IONQ, and SPT.

Avi Kapoor

Why Forte Biosciences Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket

Forte Biosciences shares rose 38.9% to $76.10 in pre-market trading after argenx SE announced plans to acquire the company for $77 per share.

Avi Kapoor

EquipmentShare, Vodafone, Circle Internet Group And Other Big Stocks Moving Higher On Friday

Dow Jones index up 50 points, Equipmentshare.Com up 15.4% on revenue guidance increase and share repurchase program. Other stocks recording gains.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-59.34M

Investing Cash Flow (TTM)

-55.00K

Financing Cash Flow (TTM)

71.76M

Free Cash Flow (TTM)

-59.39M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

12.37M

Analyst Trends and Forecast

1

1

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.5

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.37B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

8.56

Earnings Yield % (TTM)

-5.95%

Earnings Yield % (FWD)

-5.29%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$8.97

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$58.22M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

-

Volume / Avg.

0 / 1.07M

Day Range

- - -

52 Wk Range

9.91 - 77.20

Market Cap

$1.57B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

84

Short Interest

9.36%

Days to Cover

1

About

Sector

Health Care

Industry

Biotechnology

Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimm...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Forte Biosciences (FBRX) stock?

A

You can purchase shares of Forte Biosciences (NASDAQ:FBRX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Forte Biosciences (FBRX) competitors?

A

Other companies in Forte Biosciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Forte Biosciences (FBRX) stock?

A

Forte Biosciences has a consensus price target of $47.46.

Q

What is the current price for Forte Biosciences (FBRX)?

A

The stock price for Forte Biosciences (NASDAQ: FBRX) is $76.78 last updated August 12, 2026 at 4:00 PM EDT.

Q

Does Forte Biosciences (FBRX) pay a dividend?

A

There are no upcoming dividends for Forte Biosciences.

Q

When is Forte Biosciences (NASDAQ:FBRX) reporting earnings?

A

Forte Biosciences does not have any upcoming earnings scheduled.

Q

Is Forte Biosciences (FBRX) going to split?

A

There is no upcoming split for Forte Biosciences.

Q

What sector and industry does Forte Biosciences (FBRX) operate in?

A

Forte Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.